HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics

Current Cardiology Reports

Volumn 19, Issue 12, 2017, Pages

  Vitali, Cecilia ^a   Khetarpal, Sumeet A ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atherosclerosis; Cholesterol efflux capacity; Coronary heart disease (CHD); Exome array genotyping; Exome sequencing; Genome wide association study (GWAS); Genomics; High density lipoprotein cholesterol (HDL C); Reverse cholesterol transport; Single nucleotide polymorphism (SNP); Targeted resequencing

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR BI; BIOLOGICAL MARKER;

CARDIOVASCULAR RISK; CETP GENE; CHOLESTEROL METABOLISM; GALNT2 GENE; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUE; HUMAN; ISCHEMIC HEART DISEASE; KLF14 GENE; LCAT GENE; LIPG GENE; LOSS OF FUNCTION MUTATION; NONHUMAN; POPULATION RESEARCH; REGULATORY MECHANISM; REVIEW; SCARB1 GENE; TTC39B GENE; WHOLE EXOME SEQUENCING; BLOOD; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

BIOMARKERS; CHOLESTEROL, HDL; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; MOLECULAR TARGETED THERAPY; WHOLE EXOME SEQUENCING;

EID: 85032800146     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-017-0940-0     Document Type: Review

References (158)

1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–5.
2. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
3. Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med. 1964;61:888–99.
4. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222–32.
5. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;
6. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (London, England). 2012;380:572–80.
7. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–42.
8. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.
9. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.
10. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51:2032–57.
11. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10:109–21.
12. Larach DB, Cuchel M, Rader DJ. Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clinical Lipidology. 2013;8:635–48.
13. • Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science (New York, NY). 2016;351:1166–71. This paper describes the paradoxical association of a loss-of-function mutation in SCARB1 gene that confers incresed HDL-C but is associated with incresed CHD risk and supports the role of a functional SR-BI in HDL metabolism and RCT
14. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356–69.
15. McCarthy MI, Hirschhorn JN. Genome-wide association studies: past, present and future. Hum Mol Genet. 2008;17:R100–1.
16. Peters DT, Musunuru K. Functional evaluation of genetic variation in complex human traits. Hum Mol Genet. 2012;21:R18–23.
17. Willer CJ, Mohlke KL. Finding genes and variants for lipid levels after genome-wide association analysis. Curr Opin Lipidol. 2012;23:98–103.
18. Khetarpal SA, Rader DJ. Genetics of lipid traits: genome-wide approaches yield new biology and clues to causality in coronary artery disease. Biochim Biophys Acta. 1842;2014:2010–20.
19. Morrison AC, Voorman A, Johnson AD, et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet. 2013;45:899–901.
20. Voight BF, Kang HM, Ding J, et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 2012;8:e1002793.
21. Peloso GM, Timofeev N, Lunetta KL. Principal-component-based population structure adjustment in the North American Rheumatoid Arthritis Consortium data: impact of single-nucleotide polymorphism set and analysis method. BMC Proc. 2009;3(Suppl 7):S108.
22. Page CM, Baranzini SE, Mevik BH, Bos SD, Harbo HF, Andreassen BK. Assessing the power of exome chips. PLoS One. 2015;10:e0139642.
23. Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA. 2009;301:2386–8.
24. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000;1529:245–56.
25. Kunnen S, Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res. 2012;53:1783–99.
26. Mehlum A, Gjernes E, Solberg LA, Hagve TA, Prydz H. Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2000;108:336–42.
27. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3:744–9.
28. Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 1997;105:861–8.
29. Tanigawa H, Billheimer JT, Tohyama J, et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation. 2009;120:160–9.
30. Brousseau ME, Kauffman RD, Herderick EE, et al. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2000;20(2):450–8.
31. Hoeg JM, Vaisman BL, Demosky SJ Jr, et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271:4396–402.
32. Amar MJ, Shamburek RD, Vaisman B, et al. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metab Clin Exp. 2009;58:568–75.
33. Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem. 2001;276:15090–8.
34. Furbee JW Jr, Sawyer JK, Parks JS. Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem. 2002;277:3511–9.
35. Ng DS, Maguire GF, Wylie J, et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem. 2002;277:11715–20.
36. Maugeais C, Tietge UJ, Broedl UC, et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 2003;108:2121–6.
37. Jaye M, Lynch KJ, Krawiec J, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999;21:424–8.
38. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest. 2003;111:347–55.
39. Broedl UC, Maugeais C, Millar JS, et al. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ Res. 2004;94:1554–61.
40. Wiersma H, Gatti A, Nijstad N, Kuipers F, Tietge UJ. Hepatic SR-BI, not endothelial lipase, expression determines biliary cholesterol secretion in mice. J Lipid Res. 2009;50:1571–80.
41. Wang C, Nishijima K, Kitajima S, et al. Increased hepatic expression of endothelial lipase inhibits cholesterol diet-induced hypercholesterolemia and atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2017;
42. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042–50.
43. Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Circ Res. 2010;107:357–64.
44. Ko KW, Paul A, Ma K, Li L, Chan L. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res. 2005;46:2586–94.
45. Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem. 2004;279:45085–92.
46. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A. 2003;100:2748–53.
47. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870–4.
48. Wang N, Arai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem. 1998;273:32920–6.
49. Ueda Y, Royer L, Gong E, et al. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem. 1999;274:7165–71.
50. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414–7.
51. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000;20:721–7.
52. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999;274:2366–71.
53. Varban ML, Rinninger F, Wang N, et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 1998;95:4619–24.
54. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A. 1997;94:12610–5.
55. Brundert M, Ewert A, Heeren J, et al. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler Thromb Vasc Biol. 2005;25:143–8.
56. Huszar D, Varban ML, Rinninger F, et al. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler Thromb Vasc Biol. 2000;20:1068–73.
57. Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002;90:270–6.
58. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364:73–5.
59. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105–10.
60. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071–4.
61. Harder C, Lau P, Meng A, Whitman SC, McPherson R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:858–64.
62. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 2007;116:1267–73.
63. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–7.
64. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106–12.
65. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clinical Science (London, England: 1979). 2002;103:587–94.
66. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033–6.
67. Zhang J, Niimi M, Yang D, et al. Deficiency of cholesteryl ester transfer protein protects against atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2017;37:1068–75.
68. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–83.
69. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–13.
70. Howson JMM, Zhao W, Barnes DR, et al. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nat Genet. 2017;
71. Webb TR, Erdmann J, Stirrups KE, et al. Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. J Am Coll Cardiol. 2017;69:823–36.
72. Keavney B, Palmer A, Parish S, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol. 2004;33:1002–13.
73. Niu W, Qi Y. Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. Circ Cardiovasc Genet. 2015;8:114–21.
74. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248–56.
75. • Nomura A, Won HH, Khera AV, et al. Protein truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. Circ Res. 2017; This paper showed for the first time that loss-of-function coding mutations in CETP that raise HDL-C are associated with reduced risk of coronary heart disease
76. Wu Z, Lou Y, Qiu X, et al. Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach. BMC Medical Genetics. 2014;15:118.
77. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120:628–35.
78. Calabresi L, Pisciotta L, Costantin A, et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25:1972–8.
79. Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177:361–6.
80. Calabresi L, Favari E, Moleri E, et al. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis. 2009;204:141–6.
81. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112:879–84.
82. Duivenvoorden R, Holleboom AG, van den Bogaard B, et al. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol. 2011;58:2481–7.
83. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053–9.
84. Mabuchi H, Nohara A, Inazu A. Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors. Mol Cells. 2014;37(11):777–84.
85. Holleboom AG, Kuivenhoven JA, Vergeer M, et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res. 2010;51:416–21.
86. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94:223–32.
87. Tietjen I, Hovingh GK, Singaraja R, et al. Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta. 1821;2012:416–24.
88. Kiss RS, Kavaslar N, Okuhira K, et al. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol. 2007;27:1139–45.
89. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191–205.
90. van den Bogaard B, Holleboom AG, Duivenvoorden R, et al. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis. 2012;225:481–5.
91. Holleboom AG, Kuivenhoven JA, Peelman F, et al. High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations. Hum Mutat. 2011;32:1290–8.
92. Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circulation journal: official journal of the Japanese Circulation Society. 2010;74:2263–70.
93. Strauss JG, Hayn M, Zechner R, Levak-Frank S, Frank S. Fatty acids liberated from high-density lipoprotein phospholipids by endothelial-derived lipase are incorporated into lipids in HepG2 cells. The Biochemical Journal. 2003;371:981–8.
94. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res. 2005;46:896–903.
95. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 2002;43:921–9.
96. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 2002;106:1321–6.
97. Singaraja RR, Tietjen I, Hovingh GK, et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. J Lipid Res. 2014;55:1693–701.
98. Singaraja RR, Sivapalaratnam S, Hovingh K, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circ Cardiovasc Genet. 2013;6:54–62.
99. Tietjen I, Hovingh GK, Singaraja RR, et al. Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol. PLoS One. 2012;7:e37437.
100. Khetarpal SA, Edmondson AC, Raghavan A, et al. Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol. PLoS Genet. 2011;7:e1002393.
101. Paradis ME, Couture P, Bosse Y, et al. The T111I mutation in the EL gene modulates the impact of dietary fat on the HDL profile in women. J Lipid Res. 2003;44:1902–8.
102. Jensen MK, Rimm EB, Mukamal KJ, et al. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009;30:1584–9.
103. Smith CE, Arnett DK, Tsai MY, et al. Physical inactivity interacts with an endothelial lipase polymorphism to modulate high density lipoprotein cholesterol in the GOLDN study. Atherosclerosis. 2009;206:500–4.
104. Razzaghi H, Santorico SA, Kamboh MI. Population-based resequencing of LIPG and ZNF202 genes in subjects with extreme HDL levels. Front Genet. 2012;3:89.
105. Vergeer M, Cohn DM, Boekholdt SM, et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis. 2010;211:558–64.
106. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56–65.
107. Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47:1121–30.
108. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33.
109. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48:634–9.
110. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (New York, NY). 1996;271:518–20.
111. Hoekstra M. SR-BI as target in atherosclerosis and cardiovascular disease–a comprehensive appraisal of the cellular functions of SR-BI in physiology and disease. Atherosclerosis. 2017;258:153–61.
112. Ji Y, Wang N, Ramakrishnan R, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem. 1999;274:33398–402.
113. Ueda Y, Gong E, Royer L, Cooper PN, Francone OL, Rubin EM. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem. 2000;275:20368–73.
114. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699–705.
115. Trigatti B, Rayburn H, Vinals M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A. 1999;96:9322–7.
116. Acton S, Osgood D, Donoghue M, et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol. 1999;19:1734–43.
117. Osgood D, Corella D, Demissie S, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. J Clin Endocrinol Metab. 2003;88:2869–79.
118. Morabia A, Ross BM, Costanza MC, et al. Population-based study of SR-BI genetic variation and lipid profile. Atherosclerosis. 2004;175:159–68.
119. Niemsiri V, Wang X, Pirim D, et al. Impact of genetic variants in human scavenger receptor class B type I (SCARB1) on plasma lipid traits. Circ Cardiovasc Genet. 2014;7:838–47.
120. Manichaikul A, Naj AC, Herrington D, Post W, Rich SS, Rodriguez A. Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1991–9.
121. Ritsch A, Sonderegger G, Sandhofer A, et al. Scavenger receptor class B type I polymorphisms and peripheral arterial disease. Metab Clin Exp. 2007;56:1135–41.
122. Naj AC, West M, Rich SS, et al. Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Genet. 2010;3:47–52.
123. Manichaikul A, Wang XQ, Musani SK, et al. Association of the lipoprotein receptor SCARB1 common missense variant rs4238001 with incident coronary heart disease. PLoS One. 2015;10:e0125497.
124. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364:136–45.
125. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52.
126. Tang CS, Zhang H, Cheung CY, et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat Commun. 2015;6:10206.
127. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–88.
128. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis. 2001;159:187–92.
129. Kappelle PJ, Gansevoort RT, Hillege HJ, Wolffenbuttel BH, Dullaart RP. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Journal of Clinical Lipidology. 2013;7:56–64.
130. Ikewaki K, Rader DJ, Sakamoto T, et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 1993;92:1650–8.
131. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234–8.
132. Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994;94:1872–82.
133. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175–86.
134. The HPS3/TIMI55-REVEAL Collaborative Group: effects of anacetrapib in patients with atherosclerotic vascular disease. The New England Journal of Medicine 2017; August 29, 2017DOI: https://doi.org/10.1056/NEJMoa1706444
135. • Hsieh J, Koseki M, Molusky MM, et al. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature. 2016;535:303–7. This manuscript elucidated the functional genomics by which a novel GWAS locus for HDL-C at the gene TTC39B influences LXR, lipid metabolism, and atherosclerosis
136. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–97.
137. Holleboom AG, Karlsson H, Lin RS, et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab. 2011;14:811–8.
138. Roman TS, Marvelle AF, Fogarty MP, et al. Multiple hepatic regulatory variants at the GALNT2 GWAS locus associated with high-density lipoprotein cholesterol. Am J Hum Genet. 2015;97:801–15.
139. Khetarpal SA, Schjoldager KT, Christoffersen C, et al. Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents. Cell Metab. 2016;24:234–45.
140. Small KS, Hedman AK, Grundberg E, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011;43:561–4.
141. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–89.
142. Kong A, Steinthorsdottir V, Masson G, et al. Parental origin of sequence variants associated with complex diseases. Nature. 2009;462:868–74.
143. Guo Y, Fan Y, Zhang J, et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest. 2015;125:3819–30.
144. Franzen O, Ermel R, Cohain A, et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science (New York, NY). 2016;353:827–30.
145. Innocenti F, Cooper GM, Stanaway IB, et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011;7:e1002078.
146. Civelek M, Wu Y, Pan C, et al. Genetic regulation of adipose gene expression and cardio-metabolic traits. Am J Hum Genet. 2017;100:428–43.
147. Ellison RC, Zhang Y, Qureshi MM, Knox S, Arnett DK, Province MA. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147:529–35.
148. Barter P. Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction Atherosclerosis Supplements. 2011;12:265–6.
149. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344–6.
150. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.
151. • Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93. This paper was the first to report an inverse association between HDL cholesterol efflux capacity and incident CV events and showed that this was independent of HDL-C.
152. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. The Lancet Diabetes & Endocrinology. 2015;3:507–13.
153. Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K. High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis. 2015;242:318–22.
154. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696–705.
155. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.
156. El Khoury P, Waldmann E, Huby T, et al. Extended-Release niacin/laropiprant improves overall efficacy of postprandial reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2016;36:285–94.
157. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586–93.
158. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084–91.